Bio-Techne Cuts Quarterly Dividend 87.7% to $0.08 Per Share

Bio-Techne Corporation will pay a quarterly dividend of $0.08 per share on Monday, November 23rd — an 87.7% cut from its previous quarterly payout of $0.65. The Minneapolis-based life sciences company declared the reduced dividend on Tuesday, November 3rd.

Shareholders of record on Friday, November 13th will receive the payment. November 13th also marks the ex-dividend date, meaning investors must own the stock before that day to qualify. The new payout annualizes to $0.32 per share, a dividend yield of 0.4% at current prices.

What does the cut mean for coverage?

The arithmetic of coverage remains comfortable. Bio-Techne's dividend payout ratio stands at 15.4%, which indicates earnings sufficiently cover the reduced distribution.

Looking forward, analysts expect the company to earn $1.97 per share next year. At the $0.32 annualized dividend, that implies a future payout ratio of 16.2% — coverage stays intact even after the reduction.

The takeaway: the cut trims cash returned to shareholders sharply, but it leaves the payout with wide headroom against projected earnings.

How is the stock trading?

Shares of NASDAQ:TECH opened at $72.82 on Wednesday and traded down 0.0%, essentially flat. Key valuation and trading figures:

• Market capitalization: $11.44 billion
• Price-to-earnings ratio: 63.32
• P/E/G ratio: 5.28
• Beta: 1.29
• 12-month low: $43.19
• 12-month high: $72.88
• 50-day moving average: $72.50
• 200-day moving average: $63.41

The stock sits just below its 52-week high of $72.88, set against a 12-month low of $43.19 — a wide range that reflects the volatility implied by its 1.29 beta.

What did the latest quarter show?

Bio-Techne last issued its quarterly earnings data on Friday, November 6th. The numbers:

• Earnings per share: $0.44, matching the consensus estimate of $0.44
• Revenue: $299.71 million, beating the consensus estimate of $292.60 million
• Net margin: 14.00%
• Return on equity: 11.56%

On average, sell-side analysts forecast the company will post earnings per share of 1.75 for the current fiscal year.

The quarter delivered a modest revenue beat and an in-line profit, results that neither strained nor strengthened the case for the dividend decision.

Who is Bio-Techne?

Bio-Techne is a life sciences company that develops and supplies products and services used in biological research, drug development, and clinical diagnostics. Its offerings include:

• Proteins, antibodies, immunoassays, and small molecules
• Instruments and analytical tools for studying cells and biological processes
• Technologies for protein analysis, molecular diagnostics, and spatial biology

The company's portfolio includes products and services associated with brands such as R&D Systems, Tocris, ProteinSimple, and Advanced Cell Diagnostics.

Why does an 87.7% cut matter?

A reduction of this size, from $0.65 to $0.08 per quarter, removes roughly $2.28 per share in annualized payout. For a company with an $11.44 billion market capitalization and a 15.4% payout ratio, the move redirects capital that previously flowed to shareholders.

Yet the market's reaction was negligible: shares opened at $72.82 on Wednesday, down 0.0%, and remained near record levels. Investors, it appears, had already priced in the change or view the retained cash as better deployed inside the business.

In plain words: Bio-Techne cut its dividend by almost nine-tenths, kept coverage comfortably above water, and watched its stock barely move.